R&D Centers

Vision: Improving the quality of life of mankind by developing treatments for intractable and rare diseases
Goal: Becoming a global innovative pharmaceutical company by launching blockbuster products through Open Collaboration

R&D Portfolio

New drugs: Expansion of launching contury of Fexuclue and expansion of its pipeline; Launching Envlo and expansion of its pipeline; Strengthen the portfolio of autoimmune, fibrosis, metabolic and cancer treatments.; New modality in drug discovery (mRNA, TPD)

Biologics: Development of stem cell therapy for intractable and rare diseases; Expansion of Jeuveau (Nabota)’s indications; EGF Line ext.
Expansion of EGF pipeline; Development of Bio-
convergence medical devices; Identification of age-related candidate

New products: Launch Luphere Depot in the US and Japanese market; Expansion of differentiation generics and incrementally modified drugs based on DDS platform technology; The global Release of self-developed medicines

C&D (Connect & Development): Focus on cell & gene therapy development through Open Collaboration; Expansion of therapeutic areas such as anti-cancer / metabolism diseases / immuno-diseases / vaccine

R&D Objectives

Development of First-/Best-in-class drugs: Development of new drugs that benefit patients; Strengthening global leadership in developing autoimmune, fibrosis, metabolic and cancer treatments through open collaboration .; Securing capacity to discover sustainable new drug assets

Development of next-generation Biologics: Development of smart stem cell therapy; Life cycle extension of Jeuveau(Nabota); Business development of cell therapy CMO and CDMO; Development of exosome; Development of First/Best in class Biopharmaceuticals Expansion of new pipelines through Open collaborations

IMD development based on innovative platform technology: Development of long-acting injections; Development of oral biopharmaceuticals; Pipeline expansion of Nasal Spray; Generic/IMD platform technology expansion and global advancement

Expanding the scope of external R&D: Exploring cutting-edge technologies; Securing world leading therapy technologies through C&D; Maximizing future values by optimal business model

Introduction of Research Centers

Global healthcare group that leads improvement of quality of life: Daewoong's distinguished technologies, such as bio-technology, cell therapy, new drug development capability, advanced material synthesis capability and various DDS technologies, and its unique optimized strategy system to utilize external sources, Open Collaboration, are the major driving forces for strengthening R&D pipeline and research capabilities. Constructing local research centers and global research network continuously create growth momentum becoming a strong R&D based pharmaceutical company with global competitiveness

Daewoong Life Science Research Center
Lioaning Daewoong, China
India Research Center
Indonesia Bio Research Center

Daewoong Life
Science Research Institute Lioaning Daewoong, China India Research Center Indonesia Bio Research Center

Yongin Daewoong Life Science Research Center

New Drug Center: Development of innovative new drugs
New Product Center: Depot injection; Compound/time-released platform technology; Consumer health product
Bio Mecca HQ: Cell treatment medicine; Growth factor; Stem cell GMP

Shenyang Liaoning Daewoong Research Center, China

Founding year: Oct 2014
Research sectors: Generics; Liquids and suspension R&D

Liaoning Daewoong Pharmaceutical Research Center was founded in October 2014 and it is in charge of research on new liquid drugs, distinguished medicine, and health functional foods that meet demands of the Chinese market. It is the Daewoong’s open collaboration base for the three northeast provinces of China and through cooperation with the Shenyang College of Pharmacology and outstanding research institutes, it is working on developing products specialized to China, fostering outstanding human resources, and making it possible for global technologies and products to enter the market.

Hyderabad India Research Center

Founding year: Jan 2009
Research sectors: Development of distinguished medicine technology; Drafting of documents for approving products in advanced nations; Production based for entering advanced nations

The India research center established in January 2009 utilizes outstanding local researchers and experiences to develop products that can make a bridgehead into advanced pharmaceutical markets such as the US and Europe. Research is being conducted on improved new drugs such as specialized time-release drugs for diseases such as antibiotics and antipsychotics, and form-changes for easier intake, and it is also conducting research on first generics of blockbuster new drugs based on platform technologies

Rockville, MD US Local Corporation

Founding year: Dec 2009
Research sectors: Introduce products to US market and sales management; New drug/bio and generic L/O and joint research or export contracts

Daewoong Pharmaceutical has continued exchange with various research groups in the United States since 2006 and opened its local corporation in Maryland in December 2009. It plans to pioneer the US market by releasing generics through research contracts and licensing/joint research, etc., and through licensing of new drug/bio products. As a strategic base for FDA and NIH rootlets, it has made networks with a variety of CROs and has been continually supporting C&D activities and pharmaceutical technology development, while reviewing the possibility to implement new products/new technologies, and it is planning to lead globalization of R&D through the export, etc. of new drugs and technologies.

Jakarta Indonesia Bio Research Center

Founding year: Dec 2017
Research sectors: Biosimilars; New biopharmaceuticals

Daewoong Infion of Indonesia started as a joint venture in 2012 and received the outstanding biopharmaceutical technologies of Daewoong Pharmaceutical and is being operated as the base for the research, development and production of biopharmaceuticals. It will conduct research to explore new biopharmaceuticals through open collaboration with local colleges and research centers in Indonesia, and will grow into the mecca of biopharmaceuticals.